SCHEMBL4300985

SCHEMBL4300985

Cc1ccc(-n2nc(-c3ccccc3)cc2NC(=O)Nc2ccc(Oc3cc(N)ncn3)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNJ6 P48051 5/20 0.50
KCNJ3 P48549 5/20 0.50
KCNJ5 P48544 4/20 0.50
MAPK13 O15264 3/20 0.50
GRM5 P41594 1/20 0.50
MAPK14 Q16539 5/20 0.49
BRAF P15056 2/20 0.49
KDR P35968 2/20 0.49
TNNI3K Q59H18 2/20 0.49
MAPK12 P53778 1/20 0.49
MAPK11 Q15759 1/20 0.49
PTPN1 P18031 1/20 0.49
PTK2 Q05397 2/20 0.49
FLT3 P36888 1/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
NTRK1 P04629 1/20 0.47
PTK2B Q14289 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4310170 0.87 KDM4E (0.48) MAPK13MAPK14BRAFKDRTNNI3K
SCHEMBL13859627 0.80 KCNJ6 (0.69) KCNJ6KCNJ3KCNJ5BRAFNTRK1
SCHEMBL1896470 0.78 KDR (0.73) MAPK14BRAFKDRTNNI3KFLT3
SCHEMBL2213841 0.77 MAPK14 (0.72) KCNJ6KCNJ3KCNJ5MAPK13GRM5
SCHEMBL4307774 0.76 MAPK13 (0.70) MAPK13MAPK14BRAFMAPK12MAPK11
SCHEMBL4303949 0.74 KCNJ6 (0.58) KCNJ6KCNJ3KCNJ5MAPK13MAPK14
SCHEMBL14133258 0.74 PTPN1 (0.83) KCNJ6KCNJ3KCNJ5MAPK13GRM5
SCHEMBL12507772 0.73 KCNJ6 (0.62) KCNJ6KCNJ3KCNJ5GRM5MAPK14
SCHEMBL16866510 0.73 MAPK13 (0.83) MAPK13MAPK14BRAFMAPK12MAPK11
SCHEMBL4303704 0.73 MAPK14 (0.57) MAPK13MAPK14BRAFMAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131437-A1 DISUBSTITUTED UREAS AS KINASE INHIBITORS CORIUM INTERNATIONAL, INC. (US) 2009-05-21 US claimed
EP-1838700-A2 DISUBSTITUTED UREAS AS KINASE INHIBITORS Novartis AG (CH) 2007-10-03 EP claimed
WO-2006072589-A2 DISUBSTITUTED UREAS AS KINASE INHIBITORS NOVARTIS AG (CH) 2006-07-13 WO claimed
US-20090131437-A1 DISUBSTITUTED UREAS AS KINASE INHIBITORS CORIUM INTERNATIONAL, INC. (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131437-A1 DISUBSTITUTED UREAS AS KINASE INHIBITORS UCK2, ULK2, MAP3K1 KCNJ6 1465/4885KCNJ3 1539/4885KCNJ5 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.